Literature DB >> 3586496

Evidence against increased glomerular pressure initiating diabetic nephropathy.

N Bank, R Klose, H S Aynedjian, D Nguyen, L B Sablay.   

Abstract

Studies were carried out to determine whether exaggerated glomerular hydraulic pressure (PG) initiates the development of glomerular pathology and proteinuria in insulin-dependent diabetic rats. Normotensive (WKY) and hypertensive rats (SHR) were made diabetic by streptozotocin injection. One group of SHR diabetic rats was treated with antihypertensive drugs to reduce blood pressure. One week after onset of diabetes, micropuncture determinations of PG, measured by stopped-flow technique, revealed that PG was higher in WKY diabetics than in non-diabetic WKY controls, and that PG was even higher in SHR diabetics (P less than 0.05). Similarly prepared groups of animals were followed for six months, approximately one fifth to one third of the expected life span of these rats. Tail systolic blood-pressure measurements documented continuous severe systolic-hypertension in SHR diabetics, normal pressure in the WKY diabetics and hypotension in the SHR diabetics treated continuously with antihypertensive drugs. Urinary protein excretion, measured monthly, was statistically the same in all groups, with no evidence of a progressive rise in the SHR diabetics. PG measured in two rats from each group after four months of diabetes was similar to values found after one week of diabetes. Semiquantitative histologic scoring of glomerular mesangial expansion after six months of diabetes failed to demonstrate any significant difference between the normotensive WKY diabetics and the hypertensive SHR diabetics. These observations suggest that elevated PG does not in itself initiate glomerular pathology or proteinuria in diabetes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3586496     DOI: 10.1038/ki.1987.83

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Proximal tubular stop flow pressure: an index of glomerular capillary pressure?

Authors:  J M Davis
Journal:  Pflugers Arch       Date:  1990-11       Impact factor: 3.657

Review 2.  Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus?

Authors:  P T Sawicki; I Mühlhauser; T Baba; M Berger
Journal:  Diabetologia       Date:  1990-02       Impact factor: 10.122

Review 3.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 4.  Aspects of the role of intraglomerular pressure as a cause of progressive renal damage.

Authors:  M Aurell
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  The development and progression of chronic renal disease. Can it be prevented or attenuated?

Authors:  R G Narins
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  [The renin-angiotensin system in diabetic patients].

Authors:  J Mann; E Ritz
Journal:  Klin Wochenschr       Date:  1988-09-15

Review 7.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

8.  Disparate effects of insulin on isolated rabbit afferent and efferent arterioles.

Authors:  L A Juncos; S Ito
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats.

Authors:  H Wehner; G Nelischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

10.  The calcium channel blocker nisoldipine delays progression of chronic renal failure in humans (preliminary communication).

Authors:  H E Eliahou; D Cohen; A Ben-David; D Herzog; I Serban; S Gavendo; S Kapuler; N Kogan; B Hellberg
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.